Feb 01, 2024
- Corporate
Organizational and Personnel Changes
TOKYO, February 1, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the following organizational and personnel changes, effective March 1, March 28 and April 1, 2024, respectively.
[Details of Organizational Changes]
1. Establishment of PHC Solution Unit
Chugai will establish a new unit to integrate related functions for developing personalized healthcare (PHC) solutions and planning and promoting practical implementation strategies. As society’s expectations regarding the value provided by healthcare become more sophisticated and diverse, Chugai connects drugs and patients, maximizes individually optimized value, and contributes to maximizing the value created in the entire healthcare system.
PHC Solutions: Non-pharmaceutical solutions (products/services) with a focus on software as a medical device, in vitro diagnostics, companion diagnostics, and digital biomarker.
- PHC Solution Unit will be newly established, and PHC Solution Dept. and Foundation Medicine Business Dept. will be placed under it.
- Foundation Medicine Unit will be dissolved.
- Science and Technology Intelligence Dept. and Medical PHC Initiative Dept. will be dissolved after their functions have been transferred to PHC Solution Dept.
- Digital biomarker development functions of Digital Strategy Dept. will be transferred to PHC Solution Dept.
- Regulatory strategy functions for digital and medical devices of Regulatory Affairs Dept. will be transferred to PHC Solution Dept.
2. Reorganization and rename of healthcare compliance functions
Some of the functions of Healthcare Compliance Dept. will be transferred to other departments, and the compliance promotion system will be strengthened. Specifically, management function of regulations related to the provision of money and premiums such as the Fair Competition Code and Transparency Guidelines will be transferred to Risk & Compliance Dept. to enhance the effectiveness and efficiency by integrating with the company-wide compliance function. In addition, some examination and inquiry functions related the provision of money and premiums will be transferred to Marketing & Sales Div., which will lead to prompt response and strengthened autonomous compliance functions.
Healthcare Compliance Dept. will change its organizational name to Medical Information Assurance Dept. and strengthened its expertise as a supervisory organization for sales information provision activities related to advertising regulations, as well as contributing to quality assurance of information provision and improvement of the environment surrounding medical information.
- Healthcare Compliance Dept. will rename to Medical Information Assurance Dept.
- Management function of regulations related to the provision of money and premiums such as the Fair Competition Code and Transparency Guidelines will be transferred to Risk & Compliance Dept.
- Some examination and inquiry functions related the provision of money and premiums will be transferred to Marketing & Sales Div.
[Details of Personnel Changes]
Effective March 1, 2024
Associate Vice President
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Takao Suzuki |
Associate Vice President |
- |
Effective March 28, 2024
Directors
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Iwaaki Taniguchi |
Director, Executive Vice President |
Senior Vice President |
Hitoshi Iikura |
Director, Executive Vice President |
Vice President |
- The appointment of Iwaaki Taniguchi and Hitoshi Iikura as Directors is subject to approval at the 113th Annual General Meeting of Shareholders, which is scheduled to be convened on March 28, 2024.
- Hisafumi Yamada and Toshiaki Itagaki are scheduled to retire from Directors as of March 28, 2024.
Audit & Supervisory Board Members
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Mami Yunoki |
Audit & Supervisory Board Member |
- |
- The appointment of Mami Yunoki as Audit & Supervisory Board Members is subject to approval at the 113th Annual General Meeting of Shareholders, which is scheduled to be convened on March 28, 2024.
- Takaaki Nimura are scheduled to retire from Audit & Supervisory Board Members as of March 28, 2024.
Executive Officers
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Tetsuya Yamaguchi |
Executive Vice President |
Executive Vice President |
Tsukasa Kusano |
Vice President |
Vice President |
Kaori Ouchi |
Vice President |
Vice President |
Effective April 1, 2024
Directors
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Osamu Okuda |
Representative Director, President Chief Executive Officer (CEO) |
Representative Director, President Chief Executive Officer (CEO) |
Iwaaki Taniguchi |
Director, Executive Vice President |
Director, Executive Vice President |
Executive Officers
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Tetsuya Yamaguchi |
Executive Vice President |
Executive Vice President |
Shinji Hidaka |
Executive Vice President |
Executive Vice President |
Tsukasa Kusano |
Executive Vice President |
Vice President |
Kaori Ouchi |
Executive Vice President |
Vice President |
Norihisa Onozawa |
Executive Vice President |
Vice President |
Naoya Fujihara |
Vice President |
Associate Vice President |
Tomoyuki Igawa |
Vice President |
Associate Vice President |
- Satoko Shisai are scheduled to retire from Executive Vice President as of March 31, 2024.
Associate Vice Presidents
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Takao Suzuki |
Associate Vice President |
Associate Vice President |
Kazuhiko Nishi |
Associate Vice President |
Head of Medical Affairs Div. |
- Kunihiro Hattori are scheduled to retire from Associate Vice President as of March 31, 2024.
Please see the PDF file about other personnel changes.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp